This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Study Type
OBSERVATIONAL
Enrollment
10,000
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation,TACE,HAIC
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
OS
Time from enrollment to first recorded occurrence of death from any cause
Time frame: 10 years
RFS
Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first.
Time frame: 10 years
Survival time after recurrence
The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause.
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Anqing First People's Hospital
Anqing, Anhui, China
RECRUITINGAnqing Municipal Hospital
Anqing, Anhui, China
RECRUITINGBengbu First People's Hospital
Bengbu, Anhui, China
RECRUITINGThe First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
RECRUITINGThe Second Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
RECRUITINGThe People's Hospital of Bozhou
Bozhou, Anhui, China
RECRUITINGThe People's Hospital of Chizhou
Chizhou, Anhui, China
RECRUITINGThe First People's Hospital of Chuzhou
Chuzhou, Anhui, China
RECRUITINGNo.2 People's Hospital of Fuyang City
Fuyang, Anhui, China
RECRUITINGFuyang Cancer Hospital
Fuyang, Anhui, China
RECRUITING...and 28 more locations